Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Replimune has a “Moderate Buy” consensus rating from 10 analysts, with six buys, one strong buy, one hold and two sells. The average 12-month price target is $11.86.
• REPL shares opened at $14.77, near their 52-week high of $15.70, after rising above their 50-day and 200-day moving averages. The company reported a quarterly loss of $0.72 per share, missing estimates by $0.03.
• Institutional ownership is substantial at 92.53%, with BlackRock initiating a position worth about $99.2 million and several other major investors increasing their stakes. Insiders, meanwhile, sold shares primarily to cover tax obligations tied to vested equity awards.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $11.8571.

A number of equities analysts have recently weighed in on REPL shares. Wedbush raised shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price target on the stock in a research note on Friday, August 7th. Weiss Ratings cut shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 11th. BMO Capital Markets raised shares of Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price objective on the stock in a report on Tuesday, June 30th. Leerink Partners upgraded shares of Replimune Group from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $11.00 to $17.00 in a research report on Tuesday, August 4th. Finally, Wolfe Research upgraded shares of Replimune Group to an "outperform" rating in a research report on Tuesday, August 4th.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $14.77 on Monday. Replimune Group has a fifty-two week low of $1.50 and a fifty-two week high of $15.70. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00. The firm's 50-day simple moving average is $11.25 and its 200-day simple moving average is $8.06. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -4.69 and a beta of 0.88.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). As a group, equities research analysts predict that Replimune Group will post -2.78 earnings per share for the current year.

Insider Buying and Selling at Replimune Group

In related news, CAO Andrew Schwendenman sold 7,632 shares of the firm's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $98,987.04. Following the completion of the transaction, the chief accounting officer directly owned 99,425 shares of the company's stock, valued at $1,289,542.25. This trade represents a 7.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of Replimune Group stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,467.59. Following the transaction, the insider directly owned 224,215 shares of the company's stock, valued at approximately $2,908,068.55. This represents a 4.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 91,124 shares of company stock worth $1,149,244. Corporate insiders own 5.40% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in REPL. BlackRock Inc. acquired a new position in shares of Replimune Group during the 2nd quarter worth $99,171,000. RTW Investments LP grew its stake in Replimune Group by 11.6% in the 4th quarter. RTW Investments LP now owns 7,140,352 shares of the company's stock valued at $69,404,000 after acquiring an additional 744,620 shares during the last quarter. Montanova Capital LLC grew its stake in Replimune Group by 4.0% in the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company's stock valued at $48,595,000 after acquiring an additional 168,000 shares during the last quarter. State Street Corp increased its holdings in Replimune Group by 26.3% during the 4th quarter. State Street Corp now owns 3,693,107 shares of the company's stock valued at $35,897,000 after acquiring an additional 768,982 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Replimune Group by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company's stock valued at $14,579,000 after acquiring an additional 9,707 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source